202 related articles for article (PubMed ID: 15831699)
21. Genomic sequence, organization, and chromosomal localization of human JAK3.
Riedy MC; Dutra AS; Blake TB; Modi W; Lal BK; Davis J; Bosse A; O'Shea JJ; Johnston JA
Genomics; 1996 Oct; 37(1):57-61. PubMed ID: 8921370
[TBL] [Abstract][Full Text] [Related]
22. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
24. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
25. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
[TBL] [Abstract][Full Text] [Related]
26. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
27. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.
Wang Z; Liu J; Sudom A; Ayres M; Li S; Wesche H; Powers JP; Walker NP
Structure; 2006 Dec; 14(12):1835-44. PubMed ID: 17161373
[TBL] [Abstract][Full Text] [Related]
28. Critical sites for the interaction between IL-2Rgamma and JAK3 and the following signaling.
Tang W; Huo H; Zhu J; Ji H; Zou W; Xu L; Sun L; Zheng Z; Theze J; Liu X
Biochem Biophys Res Commun; 2001 May; 283(3):598-605. PubMed ID: 11341766
[TBL] [Abstract][Full Text] [Related]
29. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.
Mella P; Schumacher RF; Cranston T; de Saint Basile G; Savoldi G; Notarangelo LD
Hum Mutat; 2001 Oct; 18(4):355-6. PubMed ID: 11668621
[TBL] [Abstract][Full Text] [Related]
30. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha.
Doucet C; Giron-Michel J; Canonica GW; Azzarone B
Eur J Immunol; 2002 Sep; 32(9):2437-49. PubMed ID: 12207328
[TBL] [Abstract][Full Text] [Related]
31. Characterization and analysis of the proximal Janus kinase 3 promoter.
Aringer M; Hofmann SR; Frucht DM; Chen M; Centola M; Morinobu A; Visconti R; Kastner DL; Smolen JS; O'Shea JJ
J Immunol; 2003 Jun; 170(12):6057-64. PubMed ID: 12794134
[TBL] [Abstract][Full Text] [Related]
32. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
[TBL] [Abstract][Full Text] [Related]
33. Adapter protein Shc regulates Janus kinase 3 phosphorylation.
Mishra J; Kumar N
J Biol Chem; 2014 Jun; 289(23):15951-6. PubMed ID: 24795043
[TBL] [Abstract][Full Text] [Related]
34. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.
Lucet IS; Fantino E; Styles M; Bamert R; Patel O; Broughton SE; Walter M; Burns CJ; Treutlein H; Wilks AF; Rossjohn J
Blood; 2006 Jan; 107(1):176-83. PubMed ID: 16174768
[TBL] [Abstract][Full Text] [Related]
35. The Janus kinases (Jaks).
Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
[TBL] [Abstract][Full Text] [Related]
36. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3.
Habib T; Senadheera S; Weinberg K; Kaushansky K
Biochemistry; 2002 Jul; 41(27):8725-31. PubMed ID: 12093291
[TBL] [Abstract][Full Text] [Related]
37. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.
Russell SM; Johnston JA; Noguchi M; Kawamura M; Bacon CM; Friedmann M; Berg M; McVicar DW; Witthuhn BA; Silvennoinen O
Science; 1994 Nov; 266(5187):1042-5. PubMed ID: 7973658
[TBL] [Abstract][Full Text] [Related]
38. The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
Alexeeva M; Åberg E; Engh RA; Rothweiler U
Acta Crystallogr D Biol Crystallogr; 2015 May; 71(Pt 5):1207-15. PubMed ID: 25945585
[TBL] [Abstract][Full Text] [Related]
39. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Raivola J; Hammarén HM; Virtanen AT; Bulleeraz V; Ward AC; Silvennoinen O
Front Oncol; 2018; 8():560. PubMed ID: 30560087
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.
Komander D; Kular GS; Bain J; Elliott M; Alessi DR; Van Aalten DM
Biochem J; 2003 Oct; 375(Pt 2):255-62. PubMed ID: 12892559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
